Kinase Inhibitors Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Kinase Inhibitors Market
Kinase Inhibitors Market: By Product (Angiogenesis, m-TOR, BRAF and MEK, Bcr-Abl Tyrosine-Kinase (TKI), EGFR, PI3K, Aurora-Kinase Inhibitors, & Others), By End-User (Hospitals, Research Labs, & Others) & By Region - Forecast(2018 - 2023)
Report Code : HCR 0236
Updated Date: 16 May, 2018  

1. Kinase Inhibitors Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Kinase Inhibitors Market– Market Forces
   4.1. Drivers
      4.1.1. Growing focus of pharmaceutical companies on R&D to come up with potential medicines for treatment of cancers
      4.1.2. Rise in the in aging population
      4.1.3. Increasing incidence and frequency of various cancers
   4.2. Restraints
      4.2.1. The research and development having higher cost
      4.2.2. Complex approvals processes
      4.2.3. Stringent government policies
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of kinase inhibitors for newer applications
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Kinase Inhibitors Market, By Product
   5.1. Angiogenesis Inhibitors
   5.2. m-TOR Inhibitors
   5.3. BRAF and MEK Inhibitors
   5.4. Bcr-Abl Tyrosine-Kinase Inhibitors (TKI)
   5.5. EGFR Inhibitors
   5.6. PI3K Inhibitors
   5.7. Aurora-Kinase Inhibitors
   5.8. Others
6. Kinase Inhibitors Market, By End-User
   6.1. Hospitals
   6.2. Research Labs
   6.3. Others
7. Kinase Inhibitors Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Kinase Inhibitors – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. Takeda Pharmaceutical Company Limited
   9.2. Boehringer Ingelheim GmbH
   9.3. AstraZeneca, Eisai Co., Ltd.
   9.4. Bristol-Myers Squibb
   9.5. Glaxo SmithKline
   9.6. Incyte Corporation
   9.7. Bayer AG
   9.8. Pfizer Inc.
   9.9. Eisai Co., Ltd.
   9.10. Novartis AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll